Oura buys Counsel Health
Sep 22, 2026 – Nov 11, 2026
-
Oura files $2.2B Nasdaq IPO, with early investors capturing most proceeds
Oura Inc. filed an amended S-1 for a Nasdaq listing under ticker OURA, offering 50 million shares at $40 to $44 each for a $14.1 billion midpoint valuation, but 36.5 million of those shares are secondary sales by existing investors, leaving the company roughly $6.2 million in net proceeds after equity tax obligations.
Read this issue → -
Oura IPO is four times oversubscribed with $400M in cornerstone commitments from Eli Lilly and Dragoneer
Bloomberg reported September 25, 2026 that the Oura Inc. Nasdaq IPO is approximately four times oversubscribed, with Eli Lilly and Dragoneer Investment Group committing roughly $400 million combined as cornerstone investors, pricing expected September 29 and first trade expected September 30 under ticker OURA at a midpoint valuation of approximately $14.1 billion.
Read this issue → -
Oura buys Counsel Health
Oura signed a definitive agreement to acquire the AI primary care company Counsel Health for a reported $625 million in cash, with a close expected near the end of 2026 and Counsel's founder becoming Oura's chief clinical AI officer.
Read this issue →